Anti-CD20 monoclonal antibody (rituximab) for therapy of cd20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl

Pediatric Hematology and Oncology

Volumn 23, Issue 8, 2006, Pages 661-666

  Čulić, Srdana ^a   Armanda, Višnja ^a   Kuljis, Dubravka ^a   Kuzmic, Ivana ^a   Pranic Kragic, Ankica ^a   Jankovic, Stipan ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Nodular lymphocyte predominant Hodgkin lymphoma; Pediatric; Rituximab

Indexed keywords

BLEOMYCIN; CD20 ANTIBODY; DACARBAZINE; DOXORUBICIN; RITUXIMAB; VINBLASTINE;

ARTICLE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INFUSION; FEMALE; HEMODYNAMICS; HUMAN; HUMAN CELL; LABORATORY TEST; LUNG TOXICITY; MEDICAL SOCIETY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PHYSICAL EXAMINATION; SCHOOL CHILD; SEROLOGY; SIDE EFFECT; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 33750433239     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010600957259     Document Type: Article

References (12)

1. Karayalcin G, Behm FG, Gieser PW, et al. Lymphocyte predominant Hodgkin disease: clinicopathologic features and results of treatment-the Pediatric Oncology Group experience. Med Pediatr Oncol. 1997;29:519-525.
2. Hansmann ML, Stein H, Dallenbach F, et al. Diffuse lymphocyte-predominant Hodgkin's disease (diffuse paragranuloma): a variant of the B-cell-derived nodular type. Am J Pathol. 1991;138:29-36.
3. Seyyedi S, Luders H, Marcinjak H, et al. Nodular lymphocyte predominant Hodgkin's disease (NLPHD)-results of the German multicenter trial GPOH-HD 95. (Abstract) Leuk Lymphoma. 2001;42(Suppl 1):P-065.43
4. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte- predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection-a study of the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:2948-2952.
5. Sandoval C, Venkateswaran L, Billups C, et al. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol. 2002;24:269-273.
6. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25:684-687.
7. Ekstrand BC, Lucas JB, Horowitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285-4289.
8. Kimby E. Tolerability and safety of rituximab (MabThera®). Cancer Treat Rev. 2005;31:456-473.
9. Čulić S, Čulić V, Armanda V, et al. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatr Hematol Oncol. 2003;20:339-344.
10. Heath JA, Broxon EH, Jr, Dole MG, et al. Epstein-Barr virus-associated lymphoma in the child undergoing an autologous stem cell rescue. J Pediatr Hematol Oncol. 2002;24:60-63.
11. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98:310-314.
12. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003;101:420-424.